T-Cell Immunotherapy Landscape
Summary
This report investigates the impacts and development of T-Cell Immunotherapies within the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes within the market and how best to pivot to prioritize future changes in the market.
Scope
This 43-page report gives important, expert insight you won’t find in any other source. 17 figures throughout the report illustrate major points and trends within the T-Cell Immunotherapy market delving deep into forecasted sales and company pipelines. This report is required reading for -
- Investors that want to understand past trends impacting the T-Cell Immunotherapy landscape as well as identifying companies to invest in
- Companies that are interested in entering the T-Cell Immunotherapy landscape and where best to focus on
- Large pharma companies with investment groups or BD teams looking to see which companies lead the T-Cell Immunotherapy landscape in the past and how they led
- Small and medium pharma who want to focus their T-Cell Immunotherapy drug portfolio on future trends and are looking for partnership opportunities
- Insights on the different types of T-Cell Immunotherapies with current and novel forms
- Insights on past trends and changes that have informed the T-Cell Immunotherapy market
- Insights on the current leading T-Cell Immunotherapy drugs based on their Sales and Forecasts and other parameters
- Therapeutic and Indication insights into the T-Cell Immunotherapy market
- Insights into the future opportunities for T-Cell Immunotherapies and the companies leading in the market.
- 1 Table of Contents
- 1. Introduction to T-Cell Immunotherapy
- 1.1 Description of the different T-Cell Immunotherapy subtypes
- 2 T-Cell Immunotherapies: Previous Years in Review
- 2.1 T-Cell Immunotherapies: split by subtype
- 2.2 Top indications
- 2.3 Most popular T-cell immunotherapy targets
- 2.4 T-cell immunotherapies split by development stage
- 2.5 Most active companies in T-cell immunotherapy development
- 3 T-Cell Immunotherapies: Future Outlook
- 3.1 Top companies by T-cell immunotherapy forecast sales
- 3.2 Total T-cell immunotherapy market forecast sales
- 3.3 Top T-cell immunotherapies by forecast sales
- 3.4 Upcoming T-cell Immunotherapy launches
- 4 Key Findings
- 5 Appendix
- 5.1 Abbreviations
- 5.2 Methodology
- 5.3 About the Authors
- 5.4 About GlobalData
- 5.5 Contact Us
- List of Figures
- Timeline of T-cell immunotherapy approvals, split out by subtype
- Patent applications and grants for T-cell immunotherapies (2009–24)
- Review designations awarded, 2012–24
- Types of review designations awarded to TCIs (2004–24)
- Deals by Volume and Value, 2010–24
- Active T-cell immunotherapies split out by their subtype
- Active T-cell immunotherapies split out by indication
- Top targets by drug count: active T-cell immunotherapies
- Active T-cell immunotherapies split out by their highest development stage
- Top companies by number of active T-cell immunotherapies in their portfolio
- Deals by Type in 2024
- Top 5 companies by total TCI sales, 2024–30
- Top Drugs by Sales, 2025
- Total Market Sales, 2017–30
- T-cell immunotherapy expected launches
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook